ARCHIVES

Tasigna Shows High Response, PFS Benefit Compared to Gleevec in Phase III CML Study

This article is from The Cancer Letter archive.

Vol. 37 No. 12 | December 26, 2014

Download PDF Visit The Full Archive

Related Articles

HCT Survivors More Likely To Show Heart Disease Risk Factors

October 26, 2012

Research Integrity: Collins’ Student Falsified Data, ORI Finds

August 22, 1997

In Brief: NIDR, NCI award $2.8 Million In Grants For Oral Cancer research Centers

October 4, 1996

First Mobil NMR Scanner Goes Into Operation At Temple

June 22, 1984

NCAB Review Of Cancer Control Program Finds It Has Made Substantial Progress But Has Problems

October 13, 1978

Two New Organ Systems Working Groups to Be Considered By NCAB

October 4, 1985